Resources
149 Results (showing 71 - 80)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 8/4/2021 (updated 4/2/2024)
This program brief highlights the Alliance for Prevention and Wellness (APW) use of Overdose Detection Mapping Application Program (ODMAP) data to target a broad range of substance use prevention and education activities to ZIP codes with the highest rate of overdoses. Source: Bureau of Justice Assistance (BJA)-Supported Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP).
Posted 8/19/2021 (updated 4/2/2024)
Addiction Policy Forum, in partnership with Justice Community Opioid Innovation Network (JCOIN) and the National Judicial Task Force to Examine State Courts’ Response to Mental Illness, have released a new online course to help educate judges and court staff on the FDA-approved medications to treat opioid use disorder and their effectiveness for people involved with the criminal justice system.
The course is self-paced and takes approximately 30 minutes to complete. The course aims to prepare participants with the knowledge and information about what substance use disorder treatment involves, the differences between the types of medications used to treat opioid use disorder, and how those medications work.
Posted 8/19/2021 (updated 4/2/2024)
Have you ever felt too uncomfortable or weird (not in a nice way) after taking stims? You could have been “overamping.” Stimulants like crack/cocaine and meth can lead to side effects that are unwanted and uncomfortable or potentially dangerous. Knowing what it is and what to do can help you be prepared if it happens.
Overamping happens when the effects of a stimulant become overwhelming, distressing, and/or dangerous.Overamping is specific to “overdosing” on stims like crack, cocaine, or meth. Using the word “overamping” helps to differentiate from an opioid overdose since they are different in how it happens, how it appears, and how to respond.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/15/2021 (updated 4/2/2024)
Background: Opioid overdose has become the leading cause of death among adults between 25 and 54 years old in the U.S. The purpose of this study is to explore the social and relational factors that shape the current opioid overdose epidemic.
Posted 9/15/2021 (updated 4/2/2024)
Background: Rates of fatal overdose (OD) from synthetic opioids rose nearly 60 % from 2016 to 2018. 911 Good Samaritan Laws (GSLs) are an evidenced-based strategy for preventing OD fatality. This study describes patrol officers’ knowledge of their state’s GSL, experience with OD response, and their perspectives on strategies to prevent and respond to opioid OD.
Posted 9/22/2021 (updated 4/3/2024)
Opioid overdose deaths continue to increase in the United States, reaching 49 860 in 2019, the highest ever recorded.1 Non-Hispanic White individuals were disproportionately affected in the wave of prescription opioid deaths at the turn of the century; however, recent increases driven by heroin and fentanyl have been greater for non-Hispanic Black and Hispanic individuals.
Objectives. To examine trends in opioid overdose deaths by race/ethnicity from 2018 to 2019 across 67 HEALing Communities Study (HCS) communities in Kentucky, New York, Massachusetts, and Ohio.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 10/13/2021 (updated 4/3/2024)
Over the past twenty years a large number of new psychoactive substances (NPS) have entered and modified the recreational drug scene. Their intake has been associated with health-related risks, especially so for vulnerable populations such as people with severe mental illness, who might be at higher risk of suicidality or self-injurious behavior. This paper aims at providing an overview of NPS abuse and the effects on mental health and suicidality issues, by performing a literature review of the current related knowledge, thereby identifying those substances that, more than others, are linked to suicidal behaviors.
Posted 10/14/2021 (updated 4/3/2024)
Participants learned evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters discussed methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Robert Childs, MPH, JBS International
Christine Rodriguez, MPH, Vital Strategies